Atria Investments Inc Decreases Stake in DexCom, Inc. (NASDAQ:DXCM)

Atria Investments Inc decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 41.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,320 shares of the medical device company’s stock after selling 11,000 shares during the quarter. Atria Investments Inc’s holdings in DexCom were worth $1,027,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Crewe Advisors LLC acquired a new stake in shares of DexCom in the first quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom during the 2nd quarter worth approximately $25,000. Sachetta LLC grew its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares during the period. DT Investment Partners LLC increased its stake in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares in the last quarter. Finally, Riverview Trust Co raised its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $75.88 on Monday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $29.64 billion, a price-to-earnings ratio of 45.44, a price-to-earnings-growth ratio of 2.33 and a beta of 1.17. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a 50 day moving average price of $70.03 and a 200 day moving average price of $91.42.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DXCM. Leerink Partners lowered their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Royal Bank of Canada dropped their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Raymond James reduced their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.